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The incorporation of poly(ethylene glycol) (PEG) chains at the focal point of dendrimers results in 5 
customizable platforms where the careful selection of the PEG length, the nature of the peripheral 
groups, and the structure and generation of the dendritic block entails materials for specific 
applications in the biomedical field. In this focus article, the synthesis, properties, and biomedical 
applications of PEG-dendritic block copolymers are discussed with examples in drug and gene 
delivery, tissue repair, and diagnosis. 10 
 
Introduction 
Dendrimers are synthetic tree-like 
macromolecules composed of repetitive 
layers of branching units that emerge 15 
from a central core (Fig. 1). They are 
prepared in a controlled iterative 
fashion, through generations with nil 
dispersity, precise molecular weight, and 
discrete properties.1 Their globular 20 
architecture and size in the nanometer 
scale render dendrimers with 
applications in a plethora of fields from 
catalysis to materials science.2 In 
addition, the inherent multivalency of 25 
dendrimers allows the controlled display 
of specific drugs, targeting and imaging 
agents of interest in drug delivery (DD) 
and other biomedical applications.3 
 30 
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Linear-dendritic block copolymers, 
originally described by the group of 40 
Fréchet in the early 1990’s (Fig. 1),4,5 
constitute interesting dendritic structures 
with the ability to self-assemble in 
solution due to differences in the 
solubility properties of the blocks. 45 
Poly(ethylene glycol) (PEG) is a FDA-
approved linear hydrophilic polymer 
widely used for engineering 
nanosystems for DD and diagnosis.6 Its 
incorporation at the focal point of 50 
dendrimers grants the resulting block 
copolymers with stealth properties, 
increased solubility and circulation 
times in the blood stream, as well as 
with reduced toxicity and 55 
immunogenicity. 
This focus article highlights the use of 
PEG-dendritic block copolymers as 
versatile multivalent structures for 
biomedical applications. 60 
Synthesis of PEG-dendritic 
block copolymers 
PEG-dendritic copolymers of the types 
AB diblock, ABA triblock, and star-
shaped AnBn (A: dendritic block, B: 65 
PEG block) have been prepared 
following three main synthetic strategies 
(Fig. 1).5 
a) Direct coupling between the end 
groups of linear polymers and the 70 
reactive focal point of dendritic wedges 
(dendrons). This was the strategy 
followed by Fréchet and coworkers in 
their pioneering preparation of PEG-
dendritic block copolymers of the types 75 
AB and ABA with poly(benzyl ether) 
dendrons of generation 3 and 4 (G3, 
G4).4 
b) Chain-first: In this approach the 
dendritic block is prepared in a 80 
divergent fashion from a PEG chain at 
the focal point by taking advantage of its 
properties as a soluble polymeric 
support. This strategy was first 
described by Chapman and coworkers in 85 
1994 for the preparation of amphiphilic 
AB type copolymers incorporating N-
Boc protected poly-L-lysine (PLL) 
dendrons (up to G4).7 The general scope 
 
2  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
of this route has later been demonstrated 
in the preparation of copolymers of PEG 
with various dendritic families, 
including bis-MPA [based on 2,2-
bis(methylol)propionic acid],8 5 
poly(glycerol−succinic acid),9 
carbosilane,10 poly(amido amine) 
(PAMAM),11 gallic acid-triethylene 
glycol (GATG),12 poly(benzyl ester),13 
triazine and carbosiloxane dendrimers.14 10 
c) Dendron-first: In this approach, 
copolymers are obtained by 
polymerization of the linear block using 
a dendritic macroinitiator. This strategy, 
developed by the group of Fréchet in 15 
1994 for the anionic ring-opening 
polymerization (ROP) of -
caprolactone,15 has been more recently 
applied by Gitsov and coworkers for the 
polymerization of ethylene oxide from a 20 
G3 poly(benzyl ether) dendron.16 
 
Micelles for drug delivery 
During the last decades, polymeric 
assemblies have attracted an enormous 25 
interest due to their potential 
applications as nanoreactors, 
nanotemplates, and in DD.17 In this 
context, PEG–dendritic block 
copolymers are especially appealing due 30 
to their tunable ability (PEG length, 
dendrimer generation) to assemble into 
different nanostructures.18 Micelles 
composed of a dendritic core surrounded 
by a palisade of flexible PEG chains 35 
have emerged as nanocarriers for the 
encapsulation or covalent incorporation 
of biologically relevant molecules. The 
PEG corona in these systems ensures 
colloidal stability, improved solubility, 40 
and long circulation times in the blood 
stream,19 which in addition to their small 
size (usually below 150 nm) enables a 
passive accumulation into solid tumors 
thanks to the enhanced permeability and 45 
retention (EPR) effect.20 
The tendency of amphiphilic PEG-
dendritic block copolymers to self-
aggregate in aqueous media was already 
revealed in the early reports by the 50 
groups of Fréchet4 and Chapman.7 A 
detailed study on the properties of ABA 
copolymers composed of PEG and poly 
(benzyl ether) dendrons showed 
formation of mono- or multimolecular 55 
micelles depending on dendrimer 
generation and solvent, and the 
possibility to encapsulate hydrophobic 
molecules with high efficiency for 
periods longer than 12 months.21 Shortly 60 
after, again the group of Fréchet 
prepared related star-shaped (A4B4) 
copolymers and studied their 
aggregation behaviour as a function of 
solvent.22 Similar studies on the 65 
aggregation of AB and ABA block 
copolymers with carbosilane,10 triazine, 
and carbosiloxane dendrons14 have also 
been performed. 
Several reports have taken advantage of 70 
these aggregation properties for 
application in DD. In a series of relevant 
contributions, Fréchet and coworkers 
elegantly developed stimuli-responsive 
nanocarriers based on PEG-dendritic 75 
block copolymers. In their strategy 
towards micelles with pH-sensitivity at 
the characteristic low values of solid 
tumors and the endosome/lysosome 
cellular compartments (~5.0-6.0), 80 
hydrophobic groups were attached at the 
periphery of dendritic PLL or bis-MPA 
blocks using highly acid-sensitive acetal 
linkers (Fig. 2).23 Polymeric micelles 
were formed (20-35 nm) in aqueous 85 
media at neutral pH that encapsulated 
the fluorescent probe Nile Red. At acidic 
pH, upon hydrolysis of the acetal 
groups, block copolymers became 
hydrophilic with concomitant 90 
destabilization of the micelles and 
release of the dye. Properties such as the 
rate of release, critical micelle 
concentration (CMC), and size could be 
tuned in this system by modifying the 95 
Figure 1. Synthetic strategies towards linear-dendritic block copolymers: a) Direct coupling, b)
Chain-first, c) Dendron-first. Adapted from ref. 5. 
Figure 2. Schematic representation of pH-sensitive micelles prepared from PEG-dendritic (bis-
MPA) block copolymers functionalized with peripheral hydrophobic groups using highly acid-
sensitive acetal linkers. Reproduced with permission from ref. 23. 
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PEG length, the structure and generation 
of the dendritic block, and the nature of 
the dendrimer-acetal linker. Shortly 
after, one of the copolymers based on a 
G3 bis-MPA dendron was employed for 5 
the encapsulation of doxorubicin 
(DOX).24 In vitro toxicities revealed 
empty micelles to be relatively non-
toxic, while those encapsulating DOX 
showed toxicity similar to that of the 10 
free drug. Interestingly, differences in 
the intracellular fate of encapsulated and 
free DOX were seen. Following a 
similar strategy, the group of Fréchet 
has also developed micelles from PEG-15 
dendritic copolymers carrying peripheral 
diazonaphthoquinone residues 
(hydrophobic), which upon irradiation 
with near infrared (NIR) light, rearrange 
into more hydrophilic moieties and 20 
trigger the delivery of hydrophobic 
payloads (Nile Red).25 
 
Related examples on the use of PEG-
dendritic block copolymers (AB and 25 
ABA) for the preparation of micelles 
have been reported by the group of 
Dong.26 Copolymers hydrophobically 
functionalized with poly(-caprolactone) 
(PCL) or poly(γ-benzyl-L-glutamate) 30 
(PBLG) chains at the terminal amino 
groups of PAMAM dendrons were 
prepared by a combination of Cu(I)-
catalyzed azide-alkyne cycloaddition 
(CuAAC) and ROP. These copolymers 35 
were able to aggregate into micelles 
where DOX was encapsulated with high 
loading efficiency. The resulting system 
displayed a sustained release profile. 
The group of Malkoch has prepared 40 
analogous PEG-dendritic copolymers 
decorated with PCL chains at the 
periphery of bis-MPA dendrons, which 
revealed useful in the production of 
micelles and honeycomb membranes.27 45 
Their results indicate lower CMC for 
these copolymers compared to linear 
PEG-PCL copolymers of similar 
molecular weight. 
Luo, Lam, and coworkers have also 50 
described well-defined micelles from 
PEG-dendritic block copolymers 
hydrophobically functionalized with 
cholic acid at the periphery of PLL 
dendrons.28 The resulting copolymers 55 
were used for the encapsulation of 
paclitaxel and studied for the treatment 
of ovarian cancer in mice [paclitaxel 
(PTX) is a potent cytotoxic agent 
approved as a first line of therapy for 60 
metastatic breast cancer and tested in the 
clinic for the treatment of metastatic 
prostate cancer]. A NIR dye was also 
encapsulated to allow a real-time study 
of micelle distribution and targeting in 65 
vivo. PTX loaded micelles with size 17-
60 nm showed prolonged circulation 
times and preferential accumulation in 
ovarian cancer murine models via EPR 
effect, which resulted in enhanced 70 
therapeutic efficacy compared to FDA-
approved Taxol® and Abraxane®. 
In a complementary approach designed 
to treat bone metastases derived from 
breast and prostate cancers, Pasut and 75 
coworkers have covalently linked PTX 
at the end of the PEG chain in a PEG-
dendritic block copolymer (based on -
glutamic acid repetition units) decorated 
with four alendronate (ALN) molecules 80 
at the dendritic surface (Fig. 3).29 ALN 
is a bisphosphonate with high affinity 
for the bone mineral hydroxyapatite 
which is used as ligand for bone 
targeting. ALN also shows an effective 85 
antiangiogenic activity. The resulting 
PTX-PEG-(ALN)4 dendritic conjugate 
aggregated into micelles with PTX at the 
core and the hydrophilic ALN molecules 
exposed on the surface to confer 90 
enhanced solubility and bone targeting 
properties. These micelles demonstrated 
a great binding affinity for 
hydroxyapatite in vitro and an IC50 
comparable to that of the free drugs 95 
combination in human adenocarcinoma 
of the prostate (PC3) cells. In addition, 
the conjugate exhibited an improved 
pharmacokinetic profile compared with 
the free drugs owed to the marked 100 
increase in their half-life. 
Polyion complex (PIC) micelles 
constitute another promising type of DD 
system that can be prepared from PEG-
dendritic block copolymers. PIC 105 
micelles are formed by electrostatic 
interaction between oppositely charged 
polyions and, similarly to classical 
polymeric micelles, are characterized by 
a core-shell structure.30 Properties such 110 
as their small size, electrical neutrality, 
and narrow size distribution make these 
systems highly attractive for DD 
applications. Our research group has 
reported the preparation of remarkably 115 
stable PIC micelles (25 nm) from an 
anionic PEG-dendritic block copolymer 
of the GATG family (decorated with 27 
peripheral sulfates) and an oppositely 
charged poly(amino acid).31 Notably, 120 
these micelles displayed enhanced 
stability against dilution and ionic 
strength compared to PIC micelles from 
linear PEGylated copolymers, which has 
been ascribed to the more rigid dendritic 125 
architecture. In a similar fashion, we 
have more recently developed related 
pH-sensitive PIC micelles with potential 
application in DD and cancer therapy.32 
Applications in gene therapy 130 
Gene therapy aims the transfer of 
nucleic acids into cells to correct genetic 
defects or confer new functions. 
Figure 3. Micelles prepared by self-assembly of a PTX-PEG-(ALN)4 copolymer have shown a
great binding affinity for the bone mineral hydroxyapatite and cytotoxic activity against
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Although with an enormous potential for 
the treatment of inherited and acquired 
diseases, the clinical application of 
nucleic acids is hampered by their low 
stability under physiological conditions 5 
and poor internalization efficiency. As a 
result, vectors capable of delivering 
nucleic acids have been developed. They 
were firstly based on modified viruses, 
and more recently on cationic synthetic 10 
carriers which electrostatically interact 
with negatively charged nucleic acids.33 
Among the latter, dendrimers have 
received special attention, with PAMAM 
and poly(propylene imine) being by far 15 
those most frequently referred.34 
Unfortunately, some limitations of 
cationic delivery vectors relate to 
aggregation with blood components and 
cytotoxicity. In the case of dendrimers, 20 
PEGylation has been explored as a way 
to mask the positive charge of the 
resulting complexes (dendriplexes).34 
When PEGylation is performed at the 
focal point, the resulting PEG-dendritic 25 
block copolymers lead to sterically 
stabilized dendriplexes with lower ξ 
potential, reduced cytotoxicity, and 
increased circulation times. 
Some of the most relevant contributions 30 
of PEG-dendritic block copolymers to 
gene therapy have been described by the 
group of Park. In a series of pioneering 
works, they prepared AB and ABA 
PEG-dendritic block copolymers based 35 
on PAMAM and PLL dendrons, which 
after incubation with plasmid DNA 
(pDNA) resulted in compact 
dendriplexes with enhanced water 
solubility and reduced toxicity.35 In 40 
these examples, higher dendrimer 
generations led to more effective 
complexation to pDNA and protection 
towards degradation by DNAse I. 
Although PAMAM dendrons granted 45 
somewhat higher transfection efficiency 
(TE) than PLL (endosome buffering 
effect), low levels of TE were typically 
observed as a result of PEG limiting 
interaction with cell surfaces. 50 
Interestingly, in a more recent 
contribution, a G5 PAMAM-PEG-
PAMAM copolymer was peripherally 
decorated with arginine residues which 
afforded dendriplexes displaying 30 55 
times higher TE than the native 
dendriplex. This has been interpreted as 
arginine ligands benefiting from an 
extended repertoire of uptake 
pathways.36 60 
Langer, Hammond, and coworkers have 
exploited the incorporation of 
carbohydrates as ligands at the end of 
PEG in PEG-PAMAM block copolymers 
as a means for targeting pDNA to cells 65 
bearing carbohydrate receptors.37 
Interestingly, these authors showed 
dendriplex size to be relatively 
insensitive to dendron G and nitrogen to 
phosphate ratio (N/P), suggesting that 70 
dendriplexes consist of a single pDNA. 
Application of the same concept to 
peptide ligands has been adapted by the 
same authors and other groups for 
targeting cancer cells overexpressing 75 
clinically relevant tumor antigens.38 
More recently, in a joint effort of our 
group with that of Alonso, the ability of 
amino-fuctionalized GATG dendrimers 
and their block copolymers with PEG to 80 
complex pDNA has been evaluated.39 
Based on the variation of the dendriplex 
size and ξ potential with G, N/P, and the 
presence of PEG, dendriplexes have 
been described as core-shell 85 
nanostructures with sterically induced 
stoichiometry. A single pDNA 
condensed at the core is surrounded by a 
shell of dendrimers with a stoichiometry 
determined by the core/dendrimer 90 
relative size: the higher the dendrimer 
G, the fewer dendrimers can be 
accommodated on the dendriplex surface 
(Fig. 4). Interestingly, in the case of 
PEG-dendritic block copolymers, this 95 
results in the possibility to tune the PEG 
density on the surface, and hence in a 
means to control the steric stabilization 
of the dendriplex. 
Other biomedical applications 100 
In addition to the above supramolecular 
nanostructures, PEG-dendritic block 
copolymers have also found application 
in DD as macromolecular scaffolds and 
containers for drugs, imaging agents, 105 
targeting ligands, and other biologically 
relevant molecules. In this context it is 
worth mentioning the seminal work by 
Fréchet, Szoka, and coworkers who 
prepared A3B3 star-shaped polymers 110 
carrying G2 bis-MPA dendrons for the 
delivery of DOX.40 To achieve a 
selective drug release, acid-labile 
hydrazone linkages were selected for 
attaching DOX on the dendritic surface. 115 
The resulting water-soluble, non-toxic 
structure showed little accumulation in 
vital organs and enhanced serum half-
live compared to free drug. Similar 
strategies have later been adapted by 120 
other groups for alternative drugs, either 
covalently bound or encapsulated within 
the dendritic block of AB and ABA 
copolymers (cisplatin, 10-
hydroxycamptothecin) with promising in 125 
vitro and in vivo results.41 
In a more recent contribution, 
Albertazzi, Hawker, and coworkers have 
reported the preparation of ABA 
copolymers carrying dendrons internally 130 
functionalized with hydroxyl groups that 
were envisioned as handles for 
hydrophobic molecules.42 Multiple units 
of a coumarin, selected as model 
hydrophobic agent, were attached at the 135 
dendrimer interior through ester bonds 
that were enzymatically hydrolysed at 
the endosome (B16 mouse melanoma 
cells). 
Another interesting application of PEG-140 
dendritic block copolymers is the 
Figure 4. Schematic representation of dendriplexes prepared from a plasmid DNA (pDNA) and
two generations of PEG-dendritic (GATG) block copolymers as nanostructures with core-shell 
stoichiometry determined by steric reasons. Reproduced with permission from ref. 39. 
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preparation of biocompatible hydrogels 
for DD, tissue engineering, and wound 
healing. The group of Grinstaff has 
achieved significant success in this field 
by crosslinking PEG-dendritic 5 
copolymers as ocular sealants.9,43 
Photocrosslinkable ABA copolymers 
carrying poly(glycerol−succinic acid) 
dendrons were functionalized with 
terminal methacrylate groups and 10 
studied as sealants for corneal 
lacerations with better results than 
conventional sutures. Application of 
these and related PEG-dendritic 
hydrogels to cartilage and osteochondral 15 
repair have also been reported by the 
same group.44 
In recent years, PEG-dendritic block 
copolymers carrying paramagnetic ions 
have found application as contrast 20 
agents (CA) in magnetic resonance 
imaging (MRI). Particularly interesting 
is the use of these macromolecular CA 
in quantitative studies of microvessels 
and for prolonged angiographies, both of 25 
great interest in cancer imaging 
evaluation. Brasch and coworkers have 
prepared copolymers of the type ABA 
with PLL dendrons (various generations 
and PEG molecular weights) 30 
functionalized with peripheral Gd 
chelates.45 A copolymer with a high 
molecular weight PEG chain (20000 Da, 
large hydrodynamic radius) was 
identified in dynamic MRI assays as a 35 
promising CA in diagnosis since it leaks 
from microvessels in cancer tissue, but 
remains in circulation in benign soft 
tissues. In a related work, Shih and 
coworkers employed an ABA copolymer 40 
carrying G3 bis-MPA dendrons 
functionalized with peripheral folate 
ligands and Gd chelates in the diagnosis 
of folate receptor-positive tumors in 
mice.46 45 
From a synthetic point of view, one of 
the major difficulties in the preparation 
of dendritic CA for MRI is their 
complete surface functionalization with 
metal chelates, which often leads to 50 
mixtures of compounds with varying 
degrees of substitution. This way, not 
only the advantage of starting from 
monodisperse materials is lost, but the 
final products become strongly batch-55 
dependent. In this regard, our research 
group has recently reported the 
advantage of using CuAAC for this goal 
by allowing the complete incorporation 
of preformed Gd chelates onto the 60 
dendritic surface of PEG-GATG block 
copolymers in very high yields.47 The 
analysis of the physical and 
pharmacokinetic properties in vitro and 
in vivo of this new family of PEG-65 
dendritic CA (contrast enhancements 
similar to Gadomer-17) revealed them as 
a promising platform for the 
development of CA for MRI. 
Finally, emerging niches for biomedical 70 
application of PEG-dendritic block 
copolymers include CA for computed 
tomography48 and their use as scaffolds 
for in vivo antibody suppression.49 
Conclusions 75 
PEG-dendritic block copolymers have 
consolidated as a customizable 
multivalent platform for the design of 
materials for specific applications in the 
biomedical field. The careful selection 80 
of the PEG length, the structure and 
generation of the dendritic block, and 
the nature of the peripheral groups has 
allowed fine-tuning their solubility, 
assembly properties, and supramolecular 85 
interactions. In addition, the 
monodisperse dendritic block facilitates 
the controlled incorporation of 
biologically relevant molecules at 
specific positions with unprecedented 90 
selectivity in the polymer field. This 
way, effective systems for drug delivery, 
targeting, and diagnosis have been 
produced during the last decade, 
including micelles, polymer-drug 95 
conjugates, contrast agents, and 
hydrogels. Despite this success, 
however, challenges are still ahead 
awaiting imaginative solutions. Thus, 
the costly stepwise synthesis of dendritic 100 
structures warrants further efforts to 
develop accelerated procedures for their 
preparation. In addition, although PEG-
dendritic copolymers have revealed 
distinct advantages over their PEG-105 
linear analogs in the biomedical field, 
precise comparative studies are required 
to identify innovative functions 
associated to the branched dendritic 
architecture. 110 
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